Benzinga | Nov 19, 2021 06:02AM EST

Vertex Pharma Reports Reimbursement Deal In Spain For KAFTRIO In Combo With Ivacaftor To Treat People With Cystic Fibrosis 12 Years+ With At Least 1 F508del Mutation

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that the Spanish government has approved terms for the national reimbursement of KAFTRIO(r) (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) for eligible patients. The agreement covers people with CF ages 12 years and older who have at least one copy of the F508del mutation, regardless of the other mutation type in the CFTR gene. KAFTRIO(r) (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor can be prescribed to eligible patients by treating physicians once the medicine is listed in the national Official Gazette Nomenclator.

"The formalized agreement is an important milestone for people living with cystic fibrosis in Spain. We are pleased that the Ministry of Health recognized the value of KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor. Today's announcement means that the medicine can be prescribed to eligible patients in Spain when listed," said Ludovic Fenaux, Senior Vice President, Vertex International. "We would like to thank the Ministry of Health for its collaborative approach, as well as the CF community for their important input during this process."

With this agreement, Spain joins the group of over 25 countries -- such as Ireland, Germany, Austria, Slovenia, Croatia, Luxembourg, Denmark, Finland, France, Portugal, Italy, Switzerland and the U.K. -- where eligible patients with CF have access to the triple combination therapy.